DOCS Stock Price Today (April 2026) — Doximity, Inc. Analysis & Key Metrics 2026-04-15
Doximity, Inc. (DOCS) is trading at $23.90, up 7.42% today (as of April 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $39.55 (65.5% upside).
- Volatility remains elevated (44.40% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (9.80% YoY) alongside significant competitive pressures.
DOCS Stock Analysis: Key Metrics & Valuation (April 2026)
Concise, actionable data for investors
Doximity, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $3.48B
P/E Ratio
Forward P/E: 14.02
Revenue Growth
Year over Year
Analyst Target
+65.5% upside potential
Key Investor Questions About DOCS
What investors need to know before buying
Based on current market data, DOCS presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 57.32)
- Fundamentals say: Looking solid (debt and growth supportive)
DOCS's growth trajectory depends on its ability to expand within the Health Information Services sector while managing margin pressures.
- Future growth will depend on performance in core Health Information Services operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for DOCS investors include debt exposure and competitive dynamics in the Health Information Services industry.
- $10.69M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Health Information Services.
52-Week Trading Range
Over the past year, DOCS stock traded between $21.82 and $76.51—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 44.40% annualized volatility and β=1.44, the stock exhibits high sensitivity to market moves—making DOCS suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
GitLab, Twilio, and Doximity Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after markets benefited from a "risk-on" sentiment fueled by potential peace negotiations between the U.S. and Iran.
1 Growth Stock to Add to Your Roster and 2 We Find Risky
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
Doximity (DOCS) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Doximity (DOCS) stood at $22.25, denoting a -1.81% move from the preceding trading day.
Here is Why Doximity (DOCS) Still Appears Attractive
Doximity Inc. (NYSE:DOCS) is one of the 7 oversold stocks to buy with double-digit ROE growth. On April 8, Elizabeth Anderson from Evercore ISI downgraded Doximity Inc. (NYSE:DOCS) to In Line from Outperform with a price target from $30 to $25. The reasons for the downgrade, as highlighted by the analyst, included lower-than-expected forecasted growth […]
Can Doximity (DOCS) Turn Its Physician-Focused AI Ecosystem Into Durable Financial Strength?
In early April 2026, Doximity drew mixed attention as analysts highlighted its physician-centric AI and telehealth ecosystem while new competitive AI offerings raised questions about the resilience of traditional SaaS models. At the same time, third-party assessments pointing to a large gap between Doximity’s share price and estimated intrinsic value, alongside insider stock sales and shifting analyst views, underscored investor uncertainty about how effectively the company can convert its...
Assessing Doximity (DOCS) Valuation After Soft Guidance And Rising AI Competition Concerns
Doximity (DOCS) is back in focus after stronger than expected revenue and softer guidance, just as Anthropic’s new Managed Agents product stirs fresh questions about how AI could affect established SaaS platforms like Doximity. See our latest analysis for Doximity. At a share price of $21.05, Doximity’s recent weakness is clear, with a 30 day share price return of 13.62% and a 90 day move of 49.11%. The 1 year total shareholder return of 59.98% points to fading momentum despite earlier...
Doximity (DOCS) Slid on Concerns Over AI Disruption
ClearBridge Investments, a global equity manager, recently published first-quarter 2026 commentary for its “Mid Cap Strategy”. A copy of the letter can be downloaded here. Mid-cap stocks showed strong performance in Q1, with the Russell Midcap Index rising 1.3%, outperforming both large-cap and small-cap stocks. In contrast, large-cap equities dropped 4.2%, while small-caps increased by only 0.9%; […]
Could Anthropic Managed Agents Pressure The Doximity SaaS Business Model
Anthropic recently introduced Managed Agents, a new service that can run autonomous AI workflows for businesses. This model could reduce the need for traditional seat-based software subscriptions that charge per user. Doximity (NYSE:DOCS), which relies heavily on a SaaS model for clinicians and life sciences customers, could face a new type of competitive pressure. Doximity runs a digital platform for U.S. clinicians, combining professional networking, telehealth tools, and workflow...
Is Doximity (DOCS) One of the Stocks Set to Explode in the Next 3 Years?
Doximity, Inc. (NYSE:DOCS) earns a spot on our list of the 15 Stocks Set to Explode in the Next 3 Years. As analysts evaluate Doximity, Inc.’s (NYSE:DOCS) platform strength against recent share weakness, the company continues to enjoy positive Wall Street sentiment. As of April 6, 2026, over 75% of covering analysts gave the company […]
TEM Stock Gains 17.9% in a Year: Time to Buy, Hold or Sell?
Tempus AI rides on diagnostics growth, AI-driven data demand, and pricing gains - but persistent losses and valuation questions complicate the buy-or-sell call.
Frequently Asked Questions
Common investor questions about Doximity, Inc.
Doximity, Inc. (DOCS) is currently trading at $23.90. The RSI (14-day) is at 57.3, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $39.55 implies 65.5% upside from current levels. Volatility is high at 44.4% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Doximity, Inc. (DOCS): The trailing P/E ratio is 19.13, which is in line with broader market averages. The forward P/E is 14.02, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.63, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 4.30. Price-to-Sales is 6.72. Valuation should be compared to Health Information Services industry peers for context, as different sectors trade at different multiples.
Based on 22 analysts covering DOCS, the consensus price target is $39.55. This represents a 65.5% upside from the current price of $23.90. The range spans from a low target of $25.00 to a high target of $56.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Doximity, Inc. (DOCS) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Doximity, Inc. (DOCS) investors include: 1. High volatility (44.4% annualized)—the stock can experience significant daily price swings. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Health Information Services sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Doximity, Inc.'s (DOCS) current debt and financial health profile: Total debt stands at $10.69M. The debt-to-equity ratio is 1.09, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 6.63, indicating strong short-term liquidity. The quick ratio is 6.00. The company holds $735.13M in cash and equivalents. Free cash flow is positive at $213.63M, providing a cushion for debt servicing and shareholder returns.